What is the drug of choice (DOC) for adult cardiac arrest?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drug of Choice for Adult Cardiac Arrest

Epinephrine 1 mg IV/IO every 3-5 minutes is the drug of choice for adult cardiac arrest, regardless of rhythm. 1, 2

Primary Vasopressor: Epinephrine

Standard-dose epinephrine (1 mg) should be administered intravenously or intraosseously every 3-5 minutes during cardiac arrest. 1, 2 The American Heart Association guidelines consistently recommend this as the primary vasopressor across all cardiac arrest rhythms. 1

Timing Based on Rhythm

  • For shockable rhythms (VF/pVT): Administer epinephrine after the third defibrillation attempt if initial CPR and shocks are unsuccessful. 1, 2 Prioritize defibrillation and high-quality CPR before giving epinephrine. 1

  • For non-shockable rhythms (asystole/PEA): Give epinephrine as soon as feasible after establishing IV/IO access. 1, 2 Earlier administration is associated with improved return of spontaneous circulation (ROSC) in observational studies. 1

Mechanism and Evidence

Epinephrine works primarily through alpha-adrenergic vasoconstriction, which increases coronary perfusion pressure and cerebral perfusion pressure during CPR. 1 While epinephrine consistently improves ROSC and short-term survival to hospital admission, it does not significantly improve survival to discharge with favorable neurological outcomes. 1, 3

Critical caveat: Despite being the standard of care, epinephrine's benefit on long-term meaningful outcomes remains controversial, with some evidence suggesting potential harm to neurological recovery. 3, 4

High-Dose Epinephrine: Not Recommended

Do not use high-dose epinephrine (>1 mg per dose) routinely. 1 Multiple randomized trials demonstrate that high-dose epinephrine (0.1-0.2 mg/kg) improves ROSC but does not improve survival to discharge or neurological outcomes compared to standard dosing. 1 High-dose epinephrine may only be considered in special circumstances such as beta-blocker or calcium channel blocker overdose. 1

Vasopressin: No Advantage

Vasopressin offers no advantage over epinephrine and is not recommended as a substitute. 1 Multiple randomized trials comparing vasopressin 40 units to epinephrine 1 mg, or the combination of both drugs versus epinephrine alone, showed no difference in ROSC, survival to discharge, or neurological outcomes. 1

The 2010 guidelines allowed vasopressin as an alternative to the first or second dose of epinephrine 1, but more recent evidence has eliminated this recommendation. 1

Exception: Vasopressin-Steroid Combination

One recent trial showed that vasopressin 20 IU plus methylprednisolone 40 mg after the first dose of epinephrine increased ROSC in in-hospital cardiac arrest, though it did not improve 30-day survival or neurological outcomes. 1 This combination may be reasonable for in-hospital arrests but requires further validation. 1

Antiarrhythmic Drugs: Secondary Role

For Refractory VF/Pulseless VT

Amiodarone 300 mg IV/IO is the preferred antiarrhythmic for shock-refractory VF/pVT. 1 Administer after the third shock if VF/pVT persists despite CPR, defibrillation, and epinephrine. 1 A second dose of 150 mg may be given. 1

Lidocaine is an acceptable alternative if amiodarone is unavailable. 1 However, neither drug has been proven to improve survival to discharge or neurological outcomes in the overall population. 1 Both amiodarone and lidocaine improved survival to discharge only in the subgroup of patients with bystander-witnessed arrest, suggesting a time-dependent benefit. 1

Important consideration: Amiodarone can cause significant hypotension and bradycardia, particularly in hemodynamically unstable patients, due to its vasoactive solvents. 1, 5 Consider administering a vasopressor before amiodarone to prevent hypotension. 1

Drugs NOT Routinely Recommended

  • Sodium bicarbonate: No evidence of benefit in undifferentiated cardiac arrest and may worsen outcomes. 1 Reserve for specific situations like hyperkalemia or tricyclic antidepressant overdose. 1

  • Calcium: Not recommended routinely and may contribute to ischemic tissue injury. 1 Use only for known hypocalcemia, hyperkalemia, or calcium channel blocker toxicity. 1

  • Magnesium: Not indicated for routine VF/pVT treatment. 1 Reserve for torsades de pointes. 1

Practical Algorithm

  1. Confirm cardiac arrest and begin high-quality CPR immediately
  2. Establish IV/IO access as soon as possible 1, 6
  3. For VF/pVT: Defibrillate → CPR → Epinephrine 1 mg after 3rd shock → Continue epinephrine every 3-5 minutes → Amiodarone 300 mg if refractory 1, 2
  4. For asystole/PEA: Epinephrine 1 mg immediately → Continue every 3-5 minutes 1, 2
  5. Operationally: Give epinephrine every second CPR cycle after the initial dose 1, 2
  6. Minimize interruptions in chest compressions—drug timing is less important than high-quality CPR 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Epinephrine Administration During Cardiopulmonary Resuscitation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Emergency medicine updates: Cardiac arrest medications.

The American journal of emergency medicine, 2025

Research

Epinephrine for cardiac arrest.

Current opinion in cardiology, 2013

Guideline

Uso de Amiodarona en Shock Cardiogénico

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Post-Cardiac Arrest Care

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.